NFL-Funded Study: CBD Or Non-Invasive Vagal Nerve Stimulation - Which Is Better To Alleviate Concussion Symptoms
Portfolio Pulse from Vuk Zdinjak
electroCore, Inc.’s (NASDAQ:ECOR) gammaCore non-invasive vagus nerve stimulation (nVNS) has been selected for studies on effects of cannabinoids and alternative care on athlete pain management and performance. The studies are funded by NFL and NFLPA research grants awarded to independent medical researchers at the American Society of Pain and Neuroscience and Emory University. The nVNS will be used in a pilot study assessing non-invasive treatment of refractory post-concussion headache pain.
July 06, 2023 | 2:21 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
electroCore's gammaCore nVNS has been selected for NFL-funded studies on athlete pain management and performance. This could potentially increase the visibility and usage of the company's product.
The selection of electroCore's gammaCore nVNS for the NFL-funded studies could potentially increase the visibility and usage of the company's product. This could lead to increased sales and revenue for the company, which would likely have a positive impact on the company's stock price in the short term.
CONFIDENCE 80
IMPORTANCE 75
RELEVANCE 100